There has been increasing interest in the contents and function of the microbiota, as it relates to pediatric inflammatory diseases. Here, we discuss the factors underlying the development of the microbiota, its role in juvenile idiopathic arthritis (JIA) and prospects for therapeutic interventions in the microbiota.
INTRODUCTION
The human microbiota consists of 100 trillion bacteria, the vast majority of which are located in the intestines. Among them, they contain 3 million genes, 100 times their human host [1] . Arguably, the first observation that microbes may promote arthritis was several millennia ago, when Hippocrates observed, 'A youth does not get gout before sexual intercourse', a possible though not definite reference to reactive arthritis [2] . In addition, it has been more than a century since Elie Metchkinoff suggested that alterations in the intestinal milieu may promote improved overall health [3] . However, the tools to explore in depth the contents and function of the gut microbiota have only existed for about 10-15 years. This review will focus on the nature of the microbiota in pediatric rheumatic diseases, their potential role in disease pathogenesis, factors that influence its development and the potential for treatment through manipulation of the microbiome. To the extent that the microbiota may play a pathogenic role in the cause of juvenile idiopathic arthritis (JIA), it is important to recognize factors influencing microbial colonization.
DEVELOPMENT OF THE MICROBIOME

Early events
A developing fetus lacks a microbiome. Initial colonizers of the gut consist of aerobic organisms, such as Enterococcus and Streptococcus, which are then replaced with anaerobes such as Bifidobacterium and Lactobacillus [4 && ]. Subsequently, the infant begins to develop a more mature (adult-like) microbiota dominated by the Bacteroidetes and Firmicutes phyla. The age at which this transition begins to take place is variable, and appears to be affected by when the child transitions from a formula/breast-milk diet to table foods [4 steady state by age 3 [6] , although a more recent study [7] indicated that older children still have a distinct microbiota as compared with adults.
The type of delivery [vaginal vs. Cesarean section (C-Sections)] affects the initial colonization and may have long-term implications on the microbiota. The initial microbiota of infants delivered vaginally bears strong resemblance to their maternal microbiota, whereas that of infants delivered via C-Section is more consistent with an adult skin microbiota [8] . These alterations can last for at least 1 year [9] . Of note, there are varying indications for C-Sections, and differences were also seen between children born via elective vs. urgent C-Section, speaking to other perinatal factors that may influence the microbiota, including prematurity, perinatal illness and antibiotic use [9] . Several studies have evaluated whether mode of delivery is associated with autoimmune disease risk, with conflicting results. A Canadian study [10] did not show any such effect, whereas a Danish registry study [11 & ] showed that C-section was associated with small yet significant increases in the risk of a variety of conditions, including inflammatory bowel disease (IBD) and JIA. Thus, mode of delivery may result in altered programming of the developing microbiota, with these changes potentially manifesting themselves for many years.
Just as delivery mode can affect the neonatal microbiota, so can the infant's early diet, with differences in breast-fed vs. formula-fed infants observed [12] . Although such studies were by necessity observational, large differences were also observed in macaques assigned to formula-fed vs. breast-fed diets [13] . Although there are no long-term followup studies evaluating whether these early-life differences are sustained, a recent study [14 & ] showed that adult patients with ankylosing spondylitis were less likely to have been breast-fed as compared with healthy controls, even among their own siblings. Thus, early-life exposures have the potential to alter the microbiota, and these alterations may impact disease in the long term.
Beyond infancy, it is well established that diet and weight can affect the microbiota. Obese individuals tend to have less diversity in their microbiota [15, 16] , and the obese state appears to potentiate itself. The obese microbiota is enriched for genes producing proteins with enhanced capacity to extract nutrients from the diet [17] . That the microbiota can potentiate obesity was demonstrated by fecal transfer studies of microbiota from genetically obese leptin-deficient mice to naive germ-free mice, who gained more weight as compared with those who received microbiota from nonobese mice [17] . Thus, environment clearly impacts the gut microbiota in health and disease.
Genetic influences
Undoubtedly, the microbiota results from a complex interplay of both genetic and environmental factors. Genetic influences are in most studies difficult to evaluate fully, as closely related individuals typically share the same environment. One of the most ambitious efforts to study environmental vs. genetic effects on the microbiota was published by Turnbaugh et al. [16] , who recruited 54 twin pairs aged 21-32 years of age (31 monozygotic and 23 dizygotic) and 46 mothers. They demonstrated that the microbiotas of the monozygotic twin pairs were no more similar to each other as the dizygotic twin pairs were to each other, implying a strong environmental effect. In contrast, Si et al. [18] compared eight monozygotics and four dizygotics twin pairs, concluding that the former microbiotas were indeed more similar; however, the numbers were smaller and the article did not indicate whether the difference was statistically significant. Thus, the evidence from these twin studies points to strong environmental influences on the microbiota.
On the contrary, genome wide association studies [19 & ,20] in humans and mice show associations between the microbiota and host genetics. Additional studies [21] [22] [23] [24] have linked abundance of certain taxa to specific polymorphisms associated with inflammatory diseases (Table 1) , potentially accounting for the effects of these polymorphisms on disease risk. Nevertheless, while some genes may affect certain taxa, the overall importance of genetic vs. environmental effects remains to be determined.
Demographic influences
To explore the impact of ethnicity and sex on microbiota diversity, Chen et al. [15] studied 118 healthy adults from the Midwestern United States. They
KEY POINTS
Early-life environmental exposures, such as delivery mode, diet and antibiotics, can have long-lasting effects that may influence the future risk of autoimmune diseases.
Children with juvenile idiopathic arthritis have altered fecal microbiota, which may contribute to disease.
Therapeutic alterations of the microbiota are a promising but currently largely unfulfilled avenue of treatment for chronic inflammatory arthritis.
reported increased diversity of the microbiota in Whites as compared with non-Whites, as well as different community structures (as evidenced by principal coordinates plots) in men as compared with women, along with specific bacteria taxa whose abundance differed by race and sex. Likewise, a study [25] of 82 healthy adults living in the Washington, D.C., area showed altered microbial community structure based upon sex, as well as different abundances of organisms even at the phyla level. A study [26] of the oral microbiota also identified differences in diversity based upon ethnicity. There are clearly multiple potential reasons for these differences, and their overall significance to health is yet unknown. However, animal studies indicate that sex-based differences in the microbiota may help contribute to disease. Specifically, in the nonobese diabetic mouse model of disease, males are relatively protected as compared with females. Transfer of the microbiota from adult males to immature females resulted in alterations of the recipient's microbiota, increased production of androgens and decreased islet inflammation [27] . Thus, ethnic and sex differences affect the microbiota, and these differences may account for some of the sexual differences in autoimmune disease risk.
ALTERATIONS IN THE MICROBIOME IN PEDIATRIC RHEUMATIC DISEASES
Prior to next-generation sequencing, there was evidence that the intestinal milieu was altered in children with JIA. Specifically, Picco et al. [28] used the urinary lactulose/mannitol test to demonstrate altered intestinal permeability in children with JIA; they found it was higher in children with juvenile spondyloarthritis (SpA) compared with those with other forms of JIA, who themselves had higher levels than healthy control individuals. Several additional studies have identified evidence of subclinical intestinal inflammation in children with SpA using colonoscopy [29] , fecal calprotectin [30] or MRI [31] ; all of these studies suggest that children with at least the SpA variant of JIA may have qualitatively similar, while quantitatively fewer, intestinal abnormalities as patients with IBD. Conversely, it is well established that up to one quarter of patients with IBD have arthritis, typically SpA [32] .
Two recent studies used 16S sequencing to evaluate the contents of the fecal microbiota in children with JIA. One was an unselected group of children with newly diagnosed JIA, composed of 13 children with oligoarticular JIA, 16 with polyarticular (15 rheumatoid factor-negative) and one child with enthesitis-related arthritis (ERA), which constitutes juvenile SpA [33 && ]. This study revealed a modest but statistically significant (44 vs. 34%, P ¼ 0.04) increase in the Bacteroides genus in patients compared with controls. Stoll et al. [34 & ] studied a group of children with ERA. The primary difference identified in this study was decreased abundance of the Firmicutes, Faecalibacterium prausnitzii, in patients compared with controls (3.8 vs. 10%, P ¼ 0.008). In addition, two distinct subsets of patients were identified, one with markedly elevated abundance of Bacteroides genus and the other with high abundance of Akkermansia muciniphlia. This finding of decreased F. prausnitzii was consistent with previous findings in both pediatric and adult IBD [35] , and is consistent with observations that this organism may have anti-inflammatory properties through direct effects on cytokine production [36] , as well as increased production of short-chain fatty acids (SCFAs) such as butyrate [37] . Butyrate and other SCFAs appear to promote regulatory T-cell function [38] . Therefore, decreased abundance of F. prausnitzii may result in decreased regulation of inflammation, thus contributing to both IBD and JIA/ERA. Among children with JIA, alterations in F. praunitzii levels appear to be at least partially specific to the ERA subgroup, as evidenced by a subsequent The microbiota in pediatric rheumatic disease Stoll and Cron study [39] showing intermediate levels of this organism in JIA children without ERA, as well as the finding by Tejesvi et al. [33 && ], in which there were no reported alterations in this organism. In contrast, increased abundance of the Bacteroides genus may be a more universal finding in JIA, as demonstrated both by the Tejesvi study and by a comparison with non-ERA JIA individuals (Fig. 1) . Although the differences shown in Fig. 1 were not statistically significant (likely because of insufficient numbers of patients evaluated), they do appear to support the Tejesvi findings.
This association of the Bacteroides genus with JIA is intriguing. Although Bacteroides is not generally considered to be proinflammatory, and indeed the polysaccharide A tail of Bacteroides fragilis appears to preferentially activate regulatory T cells [40] , studies in animal models of SpA have suggested that the Bacteroides genus may be contributory to the disease. Specifically, mouse [41] and rat [42] models of SpA were both shown to have protection against the disease in the germ-free state, with reemergence of disease when the Bacteroides genus was added back. Neither of the studies in JIA was able to speciate the Bacterodes; this is a limitation of 16S sequencing in general.
Finally, the significance of increased abundance of A. muciniphila, a member of theVerrucomicrobia phylum, in a subset of JIA/ERA patients, is unclear; in a study [43 & ] of adult psoriatic arthritis patients, controls had elevated levels as compared with patients. Derrien et al. [44] postulated that as this species is known for its capacity to degrade intestinal mucins, decreased production of mucin could potentially be damaging to the gut wall, resulting in increased permeability; indeed, increased intestinal permeability has been observed in adults with ankylosing spondylitis [45] , as well as in children with JIA [28] .
To study the functional consequences of an altered microbiota, Stoll et al. [46] performed whole genome sequencing and fecal water metabolomics on children with ERA and healthy control individuals, the results of which were presented at the 2015 American College of Rheumatology conference. They found that patients had decreased taxonomic diversity, decreased genetic coverage of the metabolic map and decreased content of fecal water metabolites, including those involved in the butanoate pathway, which makes butyrate. Although decreased F. prausnitzii was not observed, it appears that plausible similar alterations in the functional potential of the microbiota may have occurred, and ultimately may be more important than the abundance of any single organism.
THERAPEUTIC POTENTIAL OF ALTERATIONS IN THE MICROBIOTA
A recent review [47] concluded that most interventions targeting the microbiota, including dietary alterations and probiotics, have not yielded dramatic results. It bears emphasis, however, that most of these studies were conducted in adults. This may be quite significant, as it appears that two interventions in adult patients with IBD that attempt to target the microbiota, exclusive enteral nutrition (EEN) and fecal microbial transplantation, both work better in younger populations [48, 49] . Similarly, there is a case report of EEN as effective therapy for a child with polyarticular JIA refractory to methotrexate and multiple tumor necrosis factor inhibitors [50] . Therefore, dietary interventions may have promise in targeting the microbiota in pediatric rheumatic diseases.
Nevertheless, it is unclear why interventions targeting the microbiota might be more effective in the pediatric population. It may be for mundane reasons, such as better adherence to the dietary intervention or shorter disease duration. However, it might also reflect the developing nature of the pediatric microbiota. That is, interventions such as dietary changes that result in reversible changes in the microbiota in adults [51] may result in long-lasting changes in young children; as an illustration, the effects of breast-milk vs. formula-milk in young macaques were observed at 12 months, despite that both groups ate the same diet beginning at 6 months of age [13] . It may be the case, then, that childhood presents a unique opportunity to alter the course of the disease through interventions targeting the microbiota. In short, the development of the microbiota may be analogous to 'original antigenic sin,' in that once the mature steady state is reached, long-term alterations may be difficult to sustain, whereas alterations in the immature microbiota might have greater likelihood of success. This possibility is consistent with observations discussed above showing that even events in the first few days of life can result in changes in the microbiota that may affect future disease risk, while dietary interventions in adults result in only transient changes. Likewise, early use of antibiotics may be a risk factor for development of both JIA and pediatric IBD [52, 53, 54 & ,55 & ], albeit not psoriasis [56] ( Table 2 ). These observations are consistent with the possibility that interventions that alter the development of the microbiota can have long-lasting effects.
However, all interventions will not likely be equally effective. Simply setting out to alter the microbiota, without solid rationale for the change, could just as easily change it for the worse as for the better, or have no effect. Along those lines, a randomized controlled trial of probiotics in children with ERA [57 & ] was no more effective than similar studies [58, 59] conducted in adults with SpA. Future studies will benefit from knowledge gained on the role of specific alterations in the microbiota of diseased humans and experimental animal models.
CONCLUSION
We are just beginning to explore the potential of microbiota-based therapy in the management of pediatric rheumatic diseases. To the extent that animal models of disease reflect the human counterparts, there is reason for optimism that such approaches may have a potential to alter if not ameliorate disease. However, there is much to be learned about the contents of the normal pediatric microbiota, the microbiota in a variety of disease states and safe and effective means of effecting long-term microbiota changes to benefit pediatric rheumatic disorders.
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